No services found
No Products found
Developing antibodies against cancer targets? Discover the world’s first Human Cancer Phage Display Library
Elevate your research with our custom antibody solutions designed to deliver results fast. Benefit from a vast expertise of over 4,000+ monoclonal and 6,000+ polyclonal antibodies produced, and experience seamless antibody development—from antigen preparation to final production. Our advanced platforms, including hybridoma generation, B-cell sorting, and phage display, ensure you receive high-quality antibodies in less than a month. Unlock the potential of your therapeutic, diagnostic, and research applications with our expertise, even against the most challenging antigens.
Innovation begins with tailored solutions. With a focus on quality, reliability, and fast turnaround times, we provide you with a full spectrum of custom antibody services designed to meet your project’s unique objectives, whether it’s developing an antibody from scratch or enhancing an existing antibody to optimize its performance.
One-Stop Solution & Integrated Full-Range Services
Gain peace of mind knowing all aspects of your antibody development project, from antigen design to antibody production, can be efficiently and seamlessly accomplished by the same expert team.
Freedom to Operate
Secure your intellectual property rights and maintain complete ownership of your assets.
10000+ antibodies produced
With 25 years of experience and over 10,000 antibodies produced, trust our experts to deliver excellence.
Proprietary platforms
We provide an added-value at each step of your antibody development process thanks to our various proprietary platforms: RocketAbsTM, MultiMabXpressTM, XtenCHOTM…
Solutions for your application
Whether you are developing antibodies for therapeutic, veterinary, diagnostic, or research applications, we have tailored solutions to meet your needs.
Experts in difficult-to-express antigen
Working on a challenging target? We have expertise in producing difficult-to-express antigens such as GPCRs or MHC-peptide complexes…
Custom polyclonal antibody production
Discover Now
Custom monoclonal antibody development
Rabbit monoclonal antibody generation by phage display
Anti-idiotypic antibodies
Custom ELISA Kits
Application guaranteed monoclonal antibody development
Discover the first Human Cancer Phage Display Library
Accelerate your custom antibody development project using our wide range of solutions.
The best compromise between diversity and developability.
Benefit from the most complete collection of antibody libraries
At ProteoGenix, our mission is to tackle all your antibody generation challenges, no matter how ambitious. Here are just a few examples of how we can support your projects:
These examples illustrate the breadth of our capabilities, but the true strength of our platform lies in its diversity, allowing us to always find the perfect solution for your project without compromise.
At ProteoGenix, we understand the regulatory, economic, and time constraints involved in antibody production, whether for therapeutic, diagnostic, or research purposes. That’s why we’ve developed three cutting-edge antibody production platforms to meet your specific needs.
Express your antibodies at the mg to g level with the best expression system on the market XtenCHOTM!
Discover MultimAbXpressTM, our proprietary platform for the production of hundreds of antibodies in parallel
The most productive IP free cell line development service
At the start of the project, you will engage in detailed discussions with one of our antibody experts so we can understand your requirements, objectives, and project timeline. This collaborative approach allows for effective custom project design and ensures that our process is aligned with your goals.
Next, we will prepare a high-quality antigen that we will use to immunize animals or for use in antibody isolation (phage display) and purification. This involves the synthesis or production of the antigen based on the specifications discussed in the project discussion phase. Attention is given to ensuring the antigen’s quality, purity, and suitability for generating the desired antibody response.
This step applies to polyclonal antibody development projects or monoclonal projects using single B cell isolation, hybridoma, or customs immune phage display library generation projects. Following antigen preparation, the selected animals will be immunized to stimulate the production of specific antibodies against the target antigen.
Once the animals have generated an immune response, blood samples will be collected, and the antibody-containing serum (polyclonal antibody production) or the B cell compartment (monoclonal antibody production) will be processed.
In cases where recombinant antibody production is required, ProteoGenix will employ advanced expression systems to produce the antibodies in a controlled laboratory setting. This ensures consistent and scalable production of the desired antibodies. Following expression, purification methods will be utilized to obtain highly pure and functional antibodies.
In scientific research, challenges abound, but so do opportunities for innovation. Our case studies highlight the real-world impact of our experts and custom antibody services. As researchers ourselves, we understand the importance of translating ideas into tangible results.
Through these narratives, we invite you to step behind the scenes and witness firsthand how Proteogenix’s tailored approach has transformed obstacles into solutions.
“I requested ProteoGenix’s services for the generation of an anti-peptide monoclonal antibody to be used in my research. I required the antibody primarily for western blotting and immunoprecipitation experiments. Although the peptide antigen proved challenging in terms of immunogenicity, ProteoGenix was able to propose a range of customised strategies to overcome production issues encountered and finally succeeded in generating not only one but three antibodies of interest, thus offering me extra options in terms of final choice and use. During the whole project, Proteogenix strived to ensure maximal quality and to adapt to my needs, and my Account Manager always provided prompt and helpful services and solutions. I can highly commend both the level of expertise and the service I received.”
Dr. David Pryce, Lecturer in Biomedical Sciences (Immunology), Bangor University, UK
“I highly recommend ProteoGenix for their fast and efficient services, providing top-quality antibodies suitable for diverse applications. Their exceptional communication, quick turnaround time, and reasonable pricing make them an excellent choice even for non-standard projects.”
Dr. Anna Blom, Professor, Lund University, Sweden
“We requested ProteoGenix’s services for the development of antibodies against a specific surface protein by phage display. Their naive human library was built from 368 donors for maximized diversity. This unique quality and their reactivity convinced us to work with them. They successfully identified various candidates that all bound well and specifically to our antigen. I appreciated their expertise for the high quality of their services as well as their good responses to my questions for this project.”
Naoya Uchida, M.D., Ph.D. at The Institute of Medical Science, The University of Tokyo, Japan
“I requested ProteoGenix’s services for the generation of neutralizing anti-COVID-19 antibodies by Phage Display. They designed an optimised strategy for this purpose which led to great results, with 4 antibodies identified as cross-reactive and neutralizing against all the current variants of concerns. During the whole project, Proteogenix strived to ensure the best quality of their final deliverables, especially by including additional screenings against emerging variants as the pandemic evolved. Their proactivity was key to obtaining promising and relevant blocking antibodies in only a few months. I highly recommend them for both their level of expertise and the personalised service they offer.”
Khelan Patel, Managing Director, Trident Biopharm Solutions, London, UK
“We are developing a novel immunotherapy and needed a highly potent monoclonal antibody. Currently the development of a novel antibody requires lengthy and expensive humanization process. We thus decided to screen for binders a human antibody library via phage display screening instead of humanizing a murine antibody. Proteogenix proposed just that. We provided our purified target antigen and in only one month several high affinity binders were obtained. We were able to quickly clone and produce a monoclonal antibody from the sequences provided. What should have taken 6 to 8 months was done in 2 for a fraction of the cost and for an equivalent quality.”
Dr. Abbas El Sahili, Senior Research Fellow, Nanyang Technological University, Singapore
The process of producing a custom monoclonal antibody starts with selecting an antigen of interest (a protein, carbohydrate, lipid, hapten, or even whole cells). The antigen is produced, purified, and characterized. The antigen is used to immunize a desired animal species to create antibodies using the hybridoma method, B cell screening method, and when using immune antibody libraries for phage display.
However, isolating antibodies from a naïve antibody phage display library does not require immunization. After immunization, antibody-producing B cells are isolated from the blood of the immunized animal, and custom antibodies are isolated and verified to bind the intended target. Depending on the requirements, the antibodies can be further modified or engineered for specific applications, such as increased stability or enhanced binding affinity.
Yes, synthetic antibodies, referred to as recombinant antibodies, can be genetically engineered thanks to advances in molecular biology and genetic engineering. This is achieved by inserting the genes encoding the antibody variable regions into an expression vector containing the conserved antibody regions. The DNA construct is expressed in bacteria, yeast, or mammalian cells needed to express large quantities of the recombinant antibody.
Recombinant antibodies allow scientists to select for certain desirable antibody traits such as antibody specificity and affinity, reduced immunogenicity (when used therapeutically) and desired features that provide scalable production of the antibody.
Antibody services refer to a range of specialized offerings provided by biotechnology companies, contract research organizations (CROs), or academic laboratories. These services are designed to support various research, diagnostic, and therapeutic applications in fields such as immunology, biotechnology, pharmaceuticals, and healthcare.
If there’s a requirement for an antibody targeting a particular antigen that is not easily procurable from standard suppliers, custom antibody production services come into play. Whether to engineer a new diagnostic, research, or clinical antibody or improve the efficacy of an already available commercial product, our custom polyclonal, monoclonal and recombinant antibody generation services deliver a superior product.
At ProteoGenix, we offer comprehensive custom antibody services under one roof, from antibody production and development to antibody engineering and characterization. We possess a wide range of phage display libraries and a proprietary protein expression system (XtenCHO), to supercharge antibody synthesis.
The key difference between monoclonal and polyclonal antibodies lies in their origin and specificity. Monoclonal antibodies (mAbs) are produced by a single B cell and bind a specific epitope (binding site) on an antigen (target).
Polyclonal antibodies (pAbs) are a combination of monoclonal antibodies derived from multiple B cells, capable of recognizing and binding to multiple epitopes on a single antigen providing broader specificity. Both polyclonal and monoclonal antibodies have their own set of strengths and weaknesses, so they can be beneficial for various purposes, depending on specific goals and requirements.
In the same way as for the cost, the development of an antibody can be extremely variable depending on the application and the method chosen. It can range from around one month for polyclonal antibodies to more than a year for a fully custom therapeutic antibody project. This difference in time is mainly explained by a difference in the complexity of the process. Developing a polyclonal antibody involves producing an antigen, immunizing animals and then collecting, testing and possibly purifying the serum. The whole process generally takes between 1 and 2 months.
The development of a therapeutic monoclonal antibody involves, in addition to the complex generation of a monoclonal antibody, various engineering steps aimed at refining the properties of the antibody. These steps may include affinity maturation, humanization, improving developability, changing the antibody’s format (bispecific, ADC, etc.), each of which can take from several weeks to several months. If you’re pressed for time, our experts can advise you on the most suitable solutions for your custom antibody development.
Generally, custom antibody production can range from a few hundred to tens of thousands of dollars, with monoclonal antibodies typically being more expensive due to the complexity of the process. The cost of making custom antibodies varies depending on several factors, including the type of antibody (monoclonal or polyclonal), the complexity of the process, the scale of production, and the specific requirements of the project.
Additionally, factors such as the choice of host species, purification methods, and additional services like antibody labeling or modification can also impact the overall cost. It’s essential to consult with service providers to get accurate cost estimates tailored to specific project requirements. At ProteoGenix, you can always request a free quote.
Founded in 2003, ProteoGenix initially focused on developing diagnostic assays and biotherapeutics targeting discovered proteins. Recognizing the value of high-quality antibodies and proteins, ProteoGenix ventured into the biopharmaceutical domain, aiming to facilitate access to clinical settings, becoming a leading antibody production company.
ProteoGenix quickly gained recognition as a trusted Contract Research Organization (CRO) and a preferred partner in the biopharmaceutical industry. Its expertise in therapeutic antibodies and custom assay development significantly enhanced the success rate of its customized therapeutics, diagnostics, as well as research tools, thereby accelerating publications, reducing time-to-market and facilitating investigational stage of new drug application.
ProteoGenix is more than just an antibody production company. It also serves as a service integrator, guiding customers from early discovery to the clinic by anticipating future biologics requirements and designing tailor-made development strategies to proactively meet those needs. Its extensive portfolio of innovative solutions spans the following six complementary service areas:
Our research and development labs constantly influence our processes with outstanding innovations like our proprietary XtenCHO™ cell line for industry-leading antibody expression in mammalian cells.
ProteoGenix also boasts an extensive catalog of over 7,000 products available in their user-friendly online shop. This comprehensive collection encompasses antibodies, proteins, ELISA kits, cell separation media, and nucleic acid purification kits, ensuring easy access to a wide range of research tools.
Got a question or need a quote? Message us and we'll get back to you 48 hours or less.
Your cart is currently empty.